SPD 427
Latest Information Update: 26 Feb 2009
Price :
$50 *
At a glance
- Originator Supernus Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 01 Jul 2002 Phase-II clinical trials in Cancer in USA (unspecified route)
- 22 Nov 2001 Phase-I clinical trials for Cancer in USA (Unknown route)
- 16 Jul 2001 Preclinical development for Cancer in USA (Unknown route)